Latest News

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations Condition: Urothelial Carcinoma Intervention: Drug: Erdafitinib Drug: Cetrelimab Purpose: The purpose of this study is to identify the recommended Phase 2 […]

Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma Condition: Upper Tract Urothelial Carcinoma Intervention: Drug: WST11 mediated vascular targeted phototherapy (VTP) Procedure: Endoscopy Purpose: The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of […]

The peak incidence of bladder cancer (BCa) occurs at 85 years but data on treatment and outcome are sparse in this age group. We aimed to compare the outcomes of high-grade nonmuscle invasive BCa (HG NMIBC) and muscle invasive BCa (MIBC) treated with standard therapies vs. palliative management in patients >85 years. Retrospective multicenter study […]

Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of all urinary bladder tumours. It is often misdiagnosed as transitional cell carcinoma, owing to the similarities in presentation. Diagnosis of SCCB is based on the WHO criteria for small cell lung carcinoma. A 58-year-old man […]

To use adaptive genetic algorithms (AGA) in combination with single-cell flow cytometry technology to develop a noninvasive test to detect bladder cancer. Fifty high grade, cystoscopy confirmed, superficial bladder cancer patients, and 15 healthy donor early morning urine samples were collected in an optimized urine collection media. These samples were then used to develop an […]

The purpose of this study was to analyze long-term complications, urodynamics, and quality of life (QoL) of patients after orthotopic ileal neobladder with orthotopic ureteral reimplantation to enrich clinical data and provide a basis for clinical use of this surgery. Between January 2007 and January 2013, 72 consecutive patients who underwent spiral ileal neobladder following […]

We used a new GP score (Gleason score multiplied by prostate-specific antigen) without the T stage as a predictive value for biochemical failure (BCF) after prostatectomy. We assessed 459 prostate cancer patients who underwent prostatectomies at our institution. Three sub-groups were defined in terms of D’Amico classification risk (low, intermediate, and high) and Gleason score […]

To compare magnetic resonance imaging-guided cognitive fusion-targeted biopsies versus computer-software-based fusion-targeted biopsies in prostate biopsy-naïve patients. This was a retrospective review of 298 consecutive patients, in which suspected clinically significant prostate cancer lesions were detected on pre-biopsy magnetic resonance imaging, and cognitive fusion-targeted biopsies or software-guided magnetic resonance imaging-ultrasound fusion-targeted biopsies was carried out. The […]

Evaluate timeliness of androgen deprivation therapy dosing, impact of dosing non-adherence on testosterone (T) and frequency of T/prostate-specific antigen (PSA) testing in prostate cancer (PCa) patients. Retrospective analyses of 22,860 PCa patients treated with luteinizing hormone-releasing hormone (LHRH) agonists. Analyses used two definitions of ‘Month’: ’28 Day Month’ (‘Late’: dosing after day 28, 84, 112, […]

The aim of the present study was to report on our early experience with hydrogel spacer (SpaceOAR) placement in combination with iodine-125 low-dose-rate brachytherapy for prostate cancer. From April 2018, SpaceOAR hydrogel spacer was placed in 100 consecutive patients undergoing iodine-125 low-dose-rate brachytherapy. Complications and the status of the placement were evaluated. Deformation of the […]